clascoterone (Winlevi) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Clascoterone, sold under the brand name Winlevi, is an antiandrogen medication which is used topically in the treatment of acne. It is also under development in a higher concentration for the treatment of androgen-dependent scalp hair loss, under the brand name Breezula. The medication is used as a cream by application to the skin, for instance the face and scalp.   Wikipedia

Chemistry

  • SMILES: CCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(=O)CO
  • InChIKey: GPNHMOZDMYNCPO-UMYBXSPQSA-N
  • Mol. Mass: 402.53
  • ALogP: 3.77
  • ChEMBL Molecule:
    cb-03-01  
More Chemistry

Pharmacology

Alternative names

cb-03-01 | cortexolone 17alpha-propionate | cortexolone 17α-propionate

Organizations (11)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Acne Vulgaris (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Acne Vulgaris (Phase 3)

Alopecia (Phase 3)

Healthy Volunteers (Phase 1)

Neoplasms (Early Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue